Free Radiation Oncology CME

Includes eleven online, self-learning activities:

• The state of prostate cancer treatment: advances in approach for advanced disease –  (1 hr CE) ACCME ACPE MOC
• Ongoing challenges and optimal approaches in the management of metastatic colorectal cancer (mCRC) – (1 hr CE) ACCME ACPE MOC
• Advanced systemic mastocytosis: from recognition to treatment (Tsewang Tashi MD) – (1 hr CE) ACCME ACPE MOC
• Pancreatic Cancer: Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting – (0.75 hr CE) ACCME ACPE MOC
• Metastatic urothelial carcinoma (mUC): Updates from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Waddah Arafat MD) – (0.75 hr CE) ACCME ACPE MOC
• Taking the next step in the management of relapsed or refractory follicular lymphoma (Eric Tam MD) – (1 hr CE) ACCME ACPE MOC
• Initial- and later-line treatment considerations in advanced renal cell carcinoma (RCC) – (1 hr CE) ACCME ACPE MOC
• Treatment considerations in relapsed or refractory chronic lymphocytic leukemia (R/R CLL): evolving approaches to an evolving disease landscape – (1 hr CE) ACCME ACPE MOC
• Contemporary treatment approaches in the management of chronic graft-versus-host disease (GVHD) – (1 hr CE) ACCME ACPE MOC
• Hitting management strategies of metastatic nasopharyngeal carcinoma on the nose – (1 hr CE) ACCME ACPE MOC
• Advanced hepatocellular carcinoma (HCC) including updates from the European Society for Medical Oncology (ESMO) 2023 – (0.75 hr CE) ACCME ACPE MOC

Target Audience: HCPs including: medical oncologists, oncology surgeons, and pathologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology, hematology, gastroenterology, urology, with some overlap in otolaryngology, transplant medicine, allergy/immunology, nephrology, and hepatology

Each year, more than 290,000 cases of breast cancer are diagnosed, making it the leading cause of cancer among females in the United States. Although earlier screening and more effective treatment options have improved outcomes among people with breast cancer, more than 43,000 people die from this type of cancer each year. Throughout the course of breast cancer management, bone health remains an important consideration. In early breast cancer, chemotherapy-induced ovarian failure and endocrine therapy can contribute to BMD loss and subsequent osteoporosis and fracture. In advanced breast cancer, about 70% of all patients will experience bone metastases, placing patients at risk for SREs. In fact, breast cancer is associated with the highest risk of SREs among all tumor types.

Maintaining bone health in patients with breast cancer requires routine monitoring and proactive management to minimize the risk of BMD loss, osteoporosis, and SREs. Guidelines therefore recommend that patients with non-metastatic breast cancer initiating aromatase inhibitors or other treatment that causes bone loss undergo dual-energy X-ray absorptiometry (DXA) scans to assess baseline BMD. Furthermore, patients at risk for osteoporosis should receive regular follow-up DXA scans to monitor for BMD loss. This represents an opportunity for ongoing education about the need for monitoring to ensure maintenance of optimal bone health.